Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Amphstar Pharmaceuticals (AMPH)

Amphastar adds David Gaugh as independent director, expands board to 11 seats

Neutral Impact 2 of 5 leadership Written later

Amphastar Pharmaceuticals appointed David Gaugh as a Class I director on July 18, 2025, increasing the board from ten to eleven authorized seats. The board determined he is independent under Nasdaq listing standards, and he was not assigned to any committees at this time.

Key points

  • Board approved increase from 10 to 11 authorized directors on July 18, 2025
  • David Gaugh appointed Class I director, term runs to the 2026 annual meeting, effective immediately
  • Initial compensation: 50% restricted stock units and 50% stock options, aggregate grant date fair value of $260,000, vesting on first anniversary

The filing

CompanyAmphstar Pharmaceuticals (AMPH)
Form8-K, current report
Filed with the SECJul 21, 2025, 4:14 PM ET
Accession number0001297184-25-000040

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 21, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.